UNLOCKING THE BODY’S NATURAL DEFENSES AGAINST CANCER

Manhattan BioSolutions is an emerging biotech company inventing novel precision biologics that harness the power of host-defense adaptations for the treatment of advanced cancers. We develop innovative tumor-targeted agents that selectively destroy cancer cells while sparing healthy tissues

Scientific Platforms

Degrader Nucleases

Developing a new generation of human nuclease therapeutics with potent anti-cancer activities. The RNA degrader (RNAD) platform utilizes engineered derivative of naturally occurring enzyme involved in host defense to selectively degrade RNA in tumors

>>>

ADCs

Developing novel biologics, Antibody-Drug Conjugates (ADCs) that target cell-surface receptors overexpressed in tumors. The ADCs are designed to selectively eliminate cancer cells via multiple immune-mediated or direct anti-tumor mechanisms

>>>
In the News
Contact Us
For business development or general inquiries, please fill out a contact form. If you’re an accredited investor, please contact us at ir @ manhattanbiosolutions.com

Office
Center Avenue, Fort Lee
New Jersey, NY 07024

Laboratory
80 5th Avenue, 1002
New York, NY 10011